Table 1. Characteristics of the Respondent GPs According to the Utilization of SGLT2 Inhibitors.

From: Real-world Practice Patterns and Barriers to SGLT2 Inhibitor Use: A Nationwide Survey of Japanese General Practitioners

Variable Active user group Passive user group p Value
(n = 508) (n = 316)
Age distribution 20s 1 (0.2) 0 (0.0) 0.047
30s 10 (2.0) 3 (0.9)
40s 36 (7.1) 20 (6.3)
50s 127 (25.0)* 58 (18.4)*
60s 205 (40.4) 126 (39.9)
70 years and older 129 (25.4)* 108 (34.2)*
No answer 0 (0.0) 1 (0.3)
Workplace Type Clinic 422 (83.0) 259 (81.9) 0.15
Hospital 85 (16.8) 55 (17.4)
No answer 1 (0.2) 2 (0.6)
Region in Japan Hokkaido/Tohoku 48 (9.5) 14 (5.1) 0.10
Kanto 154 (30.7) 79 (25.2)
Chubu/Hokuriku 69 (14.1) 53 (16.9)
Kinki 85 (17.4) 62 (20.1)
Chugoku/Shikoku 65 (13.5) 44 (14.3)
Kyushu/Okinawa 65 (13.1) 47 (15.6)
No answer 9 (1.8) 9 (2.9)
History of nephrology training Yes 134 (26.4)* 63 (19.9)* 0.01
No 374 (73.6) 250 (79.1)
No answer 0 (0.0) 3 (0.9)
Specialty Internal medicine 426 (83.9) 276 (87.3) 0.17
Cardiology 113 (22.2) 39 (12.3) <0.001
Diabetology and metabolism 93 (18.3) 43 (13.6) 0.08
Gastroenterology 96 (18.9) 63 (19.9) 0.71
Pulmonology 41 (8.1) 18 (5.7) 0.20
Neurology 14 (2.8) 15 (4.7) 0.13
Hematology 12 (2.4) 7 (2.2) 0.89
Rheumatology 12 (2.4) 10 (3.2) 0.49
Allergy 22 (4.3) 5 (1.6) 0.03
Psychiatry 7 (1.4) 6 (1.9) 0.56
Other 17 (3.3) 17 (5.4) 015
Table 2. Results of Questionnaires on CKD Medical Care According to the Utilization of SGLT2 Inhibitors.

From: Real-world Practice Patterns and Barriers to SGLT2 Inhibitor Use: A Nationwide Survey of Japanese General Practitioners

Active user group Passive user group p Value†
(n = 508) (n = 316)
Q1 Do you possess the CKD guidelines 2023?
 Yes, and I use them frequently. 121 (23.8)# 52 (16.5)# 0.02
 Yes, but I have not used them. 175 (34.4) 106 (33.5)
 No, but I would like to obtain the CKD Guidelines 2024 for GPs. 176 (34.6) 121 (38.3)
 I do not possess them and do not wish to obtain the CKD Guidelines 2024 for GPs. 32 (6.3)* 35 (11.1)*
 No answer. 4 (0.8) 2 (0.6)
Q2* What parameters do you use to assess kidney function?
 Serum creatinine level. 291 (57.3) 203 (64.2) 0.048
 eGFRcreatinine level. 491 (96.7) 289 (91.5) 0.001
 Serum cystatin C level. 74 (14.6) 33 (10.3) 0.09
 eGFRcystatinC level. 81 (15.9) 24 (7.6) < 0.001
 Creatinine clearance (24-h urine collection). 12 (2.4) 9 (1.9) 0.66
Q3 How do you diagnose patients as having CKD?
 Only by urine test. 2 (0.4)# 6 (1.9)# < 0.001
 Only by eGFR level. 29 (5.7)# 41 (13.0)#
 By both urine test and eGFR level. 370 (72.8) 234 (74.1)
 By urine test, eGFR level, and kidney imaging. 104 (20.5)# 33 (10.4)#
 No answer 3 (0.6) 2 (0.6)
Q4 Do you check urine tests for patients with CKD during regular visits?
 Perform quantitative tests for proteinuria (g/gCr). 203 (40.0)# 170 (53.8)# < 0.001
 Perform only qualitative tests for proteinuria. 205 (40.4)# 84 (26.6)#
 Do not perform urine testing. 10 (2.0) 11 (3.5)
 No answer 90 (17.7) 51 (16.1)
Q5 Do you check albuminuria in patients with diabetes during regular visits?
 Quantitative tests every 3 months. 102 (20.1)# 40 (12.7)# < 0.001
 Quantitative tests once or twice a year. 216 (42.5)# 76 (24.1)#
 Rarely perform quantitative tests. 75 (14.8)# 69 (21.8)#
 Perform only qualitative tests. 32 (6.3) 30 (9.5)
 Do not check albuminuria. 82 (16.1)# 100 (31.6)#
 No answer 1 (0.2%) 1 (0.3)
Q6 Do you evaluate BP in patients with CKD during clinic visits?
 I evaluate both office BP and home BP in the early morning. 444 (87.4)# 259 (82.0)# 0.01
 I evaluate only home BP in the early morning. 27 (5.3) 14 (4.4)
 I evaluate only office BP. 36 (7.1)# 38 (12.0)#
 I do not evaluate either. 0 (0.0)# 5 (1.6)#
 No answer 1 (0.2) 0 (0.0)
Q7 Do you prescribe RAS inhibitors to patients with CKD and hypertension?
 I prescribe them as first-line medication. 393 (77.4)# 222 (70.3)# < 0.001
 I prescribe them to patients with proteinuria. 93 (18.3) 54 (17.1)
 I rarely prescribe them. 20 (3.9)# 39 (12.3)#
 No answer 2 (0.4) 1 (0.3)
Q8* When do you discontinue RAS inhibitors in patients with CKD?
 When kidney function deteriorates. 178 (35.3) 125 (39.8) 0.20
 When the serum Cr level reaches 2 mg/dL. 122 (24.2) 72 (22.9) 0.68
 When the serum potassium level exceeds the normal range. 225 (44.6) 152 (48.4) 0.29
 I continue prescribing them for their renoprotective effects. 245 (48.6) 127 (40.4) 0.02
 I do not prescribe them to patients with CKD. 7 (1.4) 16 (5.1) 0.002
Q9* How do you evaluate salt intake in patients with CKD?
 By Tanaka’s formula using spot urine samples. 198 (40.1) 74 (24.3) < 0.001
 By direct measurement using 24-h urine collection. 2 (0.4) 6 (2.0) 0.03
 By patient interview. 164 (33.2) 114 (37.4) 0.23
 I do not evaluate salt intake by either method. 143 (28.9) 120 (39.3) 0.002
Q10* Which parameters do you use to evaluate renal anemia?
 Hemoglobin level. 500 (98.4) 300 (95.2) 0.007
 Mean corpuscular volume (MCV). 301 (59.3) 144 (45.7) < 0.001
Serum iron (Fe) level. 362 (71.3) 194 (61.6) 0.004
 Transferrin saturation (TSAT). 162 (31.9) 47 (14.9) < 0.001
 Serum ferritin level. 362 (71.3) 187 (59.4) < 0.001
 Serum erythropoietin level. 232 (45.7) 148 (47.0) 0.71
Q11 Do you prescribe erythropoiesis-stimulating agents to patients with CKD?
 Yes, I prescribe them at my own discretion. 347 (68.3)# 165 (52.2)# < 0.001
 Yes, I prescribe them when recommended by a nephrologist. 92 (18.1)# 83 (26.3)#
 No, I do not prescribe them. 63 (12.4)# 63 (19.9)#
 No answer 6 (1.2) 5 (1.6)
Q12 Do you prescribe HIF-PH inhibitors to patients with CKD?
 Yes, I prescribe them at my own discretion. 306 (60.2)# 110 (34.8)# < 0.001
 Yes, I prescribe them when recommended by a nephrologist. 102 (20.1) 78 (24.7)
 No, I do not prescribe them. 87 (17.1)# 118 (37.3)#
 No answer 13 (2.3) 10 (3.2)
Q16 How do you manage serum potassium levels in patients with CKD?
 I regularly check potassium levels and manage hyperkalemia continuously. 333 (65.6)# 150 (47.5)# < 0.001
 I check potassium regularly but provide only temporary treatment. 82 (16.1)# 73 (23.1)#
 I check potassium regularly but refer hyperkalemia management to a nephrologist. 62 (12.2)# 57 (18.0)#
 I do not check potassium but manage hyperkalemia per nephrologist instructions. 24 (4.7)# 26 (8.2)#
 I neither check nor treat hyperkalemia. 7 (1.4) 10 (3.2)
Q18 Do you evaluate serum calcium and phosphorus levels in patients with CKD?
 I regularly check both calcium and phosphorus levels. 258 (50.8)# 106 (33.5)# < 0.001
 I regularly check only calcium levels. 119 (23.4) 82 (25.9)
 I check them only in patients on vitamin D therapy. 65 (12.8) 39 (12.3)
 I do not check them but rely on nephrologists. 45 (8.9)# 63 (19.9)#
 I never check them. 16 (3.1)# 26 (8.2)#
 No answer 5 (1.0) 0 (0.0)
Q19 Do you provide dietary therapy to patients with non–dialysis-dependent CKD?
 I provide it at my clinic or hospital. 345 (67.9)# 159 (50.3)# < 0.001
 I refer patients to nephrologists for dietary therapy. 107 (21.1)# 96 (30.4)#
 I neither provide nor refer for dietary therapy. 53 (10.4)# 61 (19.3)#
 No answer 3 (0.6) 0 (0.0)
Q20* What types of CKD dietary therapy do you provide?
 Restriction of daily salt intake. 479 (96.8) 284 (94.0) 0.06
 Restriction of daily protein intake. 322 (65.1) 189 (62.6) 0.48
 Guidance on appropriate daily calorie intake. 171 (34.5) 89 (29.5) 0.14
 Restriction of daily phosphate intake. 223 (45.1) 97 (32.1) < 0.001
Table 3. Results of Questionnaires on CKD Collaborative Care between GPs and Nephrologists According to the Utilization of SGLT2 Inhibitors.

From: Real-world Practice Patterns and Barriers to SGLT2 Inhibitor Use: A Nationwide Survey of Japanese General Practitioners

Active user group Passive user group p Value†
(n = 508) (n = 316)
Q21 Is CKD collaborative care between GPs and nephrologists active in your region?
 Yes, fully active. 128 (25.2) 71 (22.5) 0.64
 Yes, partially active. 234 (46.1) 149 (47.2)
 No, it does not work well. 108 (21.3) 64 (20.3)
 No, and there is no CKD collaborative care between GPs and nephrologists. 36 (7.1) 31 (9.8)
 No answer 2 (0.4) 1 (0.3)
Q22 Do you know any nephrologists whom you can consult regarding patients with CKD?
 Yes, I know several nephrologists available for consultation. 385 (75.8) 241 (67.3) 0.09
 Yes, I know only one nephrologist available for consultation. 71 (14.0) 31 (9.8)
 No 48 (9.4) 43 (13.6)
 No answer 4 (0.8) 1 (0.3)
Q23 How is your relationship with nephrologists available for consultation?
 I know them well personally. 169 (33.3)# 71 (22.5)# 0.003
 I know only their names. 277 (54.5) 190 (60.1)
 I do not know them well. 58 (11.4)# 54 (17.1)#
 No answer 4 (0.8) 1 (0.3)
Q24 Do you use the referral criteria for CKD consultation recommended in the CKD Guidelines (Japanese Society of Nephrology)?
 I use it often. 86 (16.9) 38 (12.0) 0.004
 I use it sometimes. 230 (45.3)# 120 (38.0)#
 I rarely use them. 100 (19.7) 64 (20.3)
 I know about them but do not use them. 70 (13.8)# 73 (23.1)#
 I do not know about them. 19 (3.7) 19 (6.0)
 No answer 3 (0.6) 2 (0.6)
Q25* For which patients with CKD do you usually consult nephrologists?
 With evident proteinuria (> 0.5 g/gCr) 294 (59.6) 187 (59.4) 0.94
 With both proteinuria and hematuria 250 (50.7) 117 (37.1) < 0.001
 With eGFR < 45 mL/min/1.73 m2 313 (63.5) 218 (69.2) 0.10
 With rapid eGFR decline 420 (85.2) 264 (83.8) 0.60
 With worsening symptoms including edema 208 (42.2) 155 (49.2) 0.05
 With worsening control of blood pressure or glucose 87 (17.6) 72 (22.2) 0.07
 With need for dietary counseling 128 (26.0) 90 (28.6) 0.42
 With need for explanation of kidney replacement therapy or conservative kidney management 313 (63.5) 173 (54.9) 0.02
Q28* What CKD-related treatments would you like nephrologists to provide?
 Salt reduction counseling 192 (39.0) 121 (37.7) 0.92
 CKD-specific dietary counseling 326 (66.3) 221 (70.6) 0.20
 Management of blood pressure 124 (25.2) 112 (35.8) 0.001
 Management of plasma glucose 60 (12.2) 58 (18.5) 0.01
 Treatment for renal anemia 181 (36.8) 149 (47.6) 0.002
 Treatment of electrolyte abnormalities or metabolic acidosis 289 (58.7) 188 (60.1) 0.71
 Explanation of kidney replacement therapy or conservative kidney management 412 (83.7) 265 (84.7) 0.73
Q29 Are you satisfied with nephrologists’ CKD consultation?
 Completely satisfied 129 (26.1) 58 (18.4) 0.11
 Satisfied sometimes 214 (43.2) 150 (47.6)
 Neither satisfied nor dissatisfied 114 (23.0) 84 (26.7)
 Occasionally dissatisfied 28 (5.7) 18 (5.7)
 Not satisfied at all 6 (1.2) 1 (0.3)
 No answer 4 (0.8) 4 (1.3)
Q30* Which aspects of the consultation were unsatisfactory?
 Insufficient patient counseling or explanation 60 (12.2) 34 (10.9) 0.57
 Insufficient feedback to GPs 83 (16.8) 51 (16.3) 0.84
 Inadequate treatment (e.g., no change in medication) 99 (20.1) 59 (18.8) 0.67
 Insufficient counseling by nutritionists or pharmacists 48 (9.7) 31 (9.9) 0.94
Table 4. Results of Logistic Regression Analysis Identifying Independent Factors Associated with the Active User Group.

From: Real-world Practice Patterns and Barriers to SGLT2 Inhibitor Use: A Nationwide Survey of Japanese General Practitioners

Question Answer Reference group p Value Exp(B) 95 % CI
Specialty Cardiology Yes No 0.03 1.84 [1.06-3.19]
Rheumatology Yes No 0.042 0.28 [0.08-0.96]
Allergy Yes No 0.005 6.13 [1.74-21.56]
Q2 Use of serum cystatin C level to evaluate kidney function Yes No 0.011 2.05 [1.18-3.60]
Q3 Diagnosis of CKD by both urine test and eGFR level By both urine test and eGFR level Only by urine test 0.042 15.55 [1.11-218.96]
Diagnosis by urine test, eGFR level, and kidney imaging By urine test, eGFR level, and kidney imaging examination Only by urine test 0.01 34.80 [2.30-527.49]
Q5 Occasional quantitative testing for albuminuria Occasional check quantitative tests for albuminuria No quantitative testing 0.031 1.67 [1.05-2.67]
Frequent quantitative testing for albuminuria Frequent check of quantitative tests for albuminuria No quantitative testing 0.039 1.96 [1.04-3.71]
Q9 Estimation of daily salt intake by 24-h urine collection Yes No 0.001 0.04 [0.006-0.23]
Q10 Use of hemoglobin level to evaluate renal anemia Yes No 0.017 4.52 [1.31-15.66]
Use of transferrin saturation (TSAT) to evaluate renal anemia Yes No 0.038 1.72 [1.03-2.87]
Q12 Prescribes HIF-PH inhibitors at their own discretion To prescribe HIF-PH inhibitors with my own discretion Does not prescribe HIF-PH inhibitors 0.003 2.10 [1.28-3.45]
Q19 Provides dietary therapy for patients with CKD To provide dietary therapy at my clinics/hospitals Does not provide dietary therapy 0.003 2.56 [1.37-4.76]
Q25 Refers patients with evident proteinuria (> 0.5 g/gCr) to nephrologists Yes No 0.017 0.57 [0.36-0.90]
Refers patients with both proteinuria and hematuria to nephrologists Yes No 0.002 2.03 [1.29-3.19]
Q27 Consults nephrologists for proteinuria > 1.0 g/gCr or (2+) by qualitative test >1.0g/gCr or (2+) by qualitative proteinuria test > 0.15 g/gCr or (±) by qualitative test 0.016 2.62 [1.19-5.75]
PAGE TOP